Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care

Bruce R. Schackman, Joseph O. Merrill, Dennis McCarty, Jeffrey Levi, Christine Lubinski

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume43
Issue numberSUPPL. 4
DOIs
StatePublished - Dec 15 2006

Fingerprint

Buprenorphine
Primary Health Care
HIV
Opioid Analgesics
Substance-Related Disorders
Electronic Health Records
Drug and Narcotic Control
Confidentiality
Virus Diseases
Licensure
Therapeutics
Health Personnel
Cost-Benefit Analysis
Alcohols
Education
Health
Research

ASJC Scopus subject areas

  • Immunology

Cite this

Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. / Schackman, Bruce R.; Merrill, Joseph O.; McCarty, Dennis; Levi, Jeffrey; Lubinski, Christine.

In: Clinical Infectious Diseases, Vol. 43, No. SUPPL. 4, 15.12.2006.

Research output: Contribution to journalArticle

Schackman, Bruce R. ; Merrill, Joseph O. ; McCarty, Dennis ; Levi, Jeffrey ; Lubinski, Christine. / Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. In: Clinical Infectious Diseases. 2006 ; Vol. 43, No. SUPPL. 4.
@article{b1fd5bd6c4ae4e259e20a34ceaa6ef07,
title = "Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care",
abstract = "Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the {"}value for money{"} of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.",
author = "Schackman, {Bruce R.} and Merrill, {Joseph O.} and Dennis McCarty and Jeffrey Levi and Christine Lubinski",
year = "2006",
month = "12",
day = "15",
doi = "10.1086/508190",
language = "English (US)",
volume = "43",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care

AU - Schackman, Bruce R.

AU - Merrill, Joseph O.

AU - McCarty, Dennis

AU - Levi, Jeffrey

AU - Lubinski, Christine

PY - 2006/12/15

Y1 - 2006/12/15

N2 - Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.

AB - Treatment for substance abuse and human immunodeficiency virus (HIV) infection historically have come from different providers, often in separate locations, and have been reimbursed through separate funding streams. We describe policy and financing challenges faced by health care providers seeking to integrate buprenorphine, a new treatment for opioid dependence, into HIV primary care. Regulatory challenges include licensing and training restrictions imposed by the Drug Addiction Treatment Act of 2000 and confidentiality regulations for alcohol and drug treatment records. Potential responses include the development of local training programs and electronic medical records. Addressing the complexity of funding sources for integrated care will require administrative support, up-front investments, and federal and state leadership. A policy and financing research agenda should address evidence gaps in the rationales for regulatory restrictions and should include cost-effectiveness studies that quantify the "value for money" of investments in integrated care to improve health outcomes for HIV-infected patients with opioid dependence.

UR - http://www.scopus.com/inward/record.url?scp=33845418372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845418372&partnerID=8YFLogxK

U2 - 10.1086/508190

DO - 10.1086/508190

M3 - Article

C2 - 17109311

AN - SCOPUS:33845418372

VL - 43

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 4

ER -